Neuland Laboratories Ltd.

“Neuland Laboratories is a legitimately strong CDMO franchise with a widening regulatory moat, improving ROIC, and credible decade-long reinvestment runway in complex small-molecule APIs and peptides — but at ~49x forward earnings and ~10x revenue, the transformation premium is fully baked in, probability-weighted 10-year returns are merely adequate (~8-11% annualised), and a single FDA enforcement action represents a permanent-impairment tail risk that is not compensated at this price; the right action is to track for a 30-35% re-rating before initiating or adding.”